NO20083059L - Pyrimidinderivater - Google Patents

Pyrimidinderivater

Info

Publication number
NO20083059L
NO20083059L NO20083059A NO20083059A NO20083059L NO 20083059 L NO20083059 L NO 20083059L NO 20083059 A NO20083059 A NO 20083059A NO 20083059 A NO20083059 A NO 20083059A NO 20083059 L NO20083059 L NO 20083059L
Authority
NO
Norway
Prior art keywords
relates
compounds
pyrimidine
ephb4
epha2
Prior art date
Application number
NO20083059A
Other languages
English (en)
Norwegian (no)
Inventor
Jason Grant Kettle
Jon Read
Andrew Leach
Bernard Christope Barlaam
Richard Ducray
Christine Marie Paul La Brempt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229185&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083059(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083059L publication Critical patent/NO20083059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20083059A 2006-01-26 2008-07-09 Pyrimidinderivater NO20083059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76238706P 2006-01-26 2006-01-26
PCT/GB2007/000251 WO2007085833A2 (fr) 2006-01-26 2007-01-25 Derives de pyrimidine

Publications (1)

Publication Number Publication Date
NO20083059L true NO20083059L (no) 2008-10-22

Family

ID=38229185

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083059A NO20083059L (no) 2006-01-26 2008-07-09 Pyrimidinderivater

Country Status (16)

Country Link
US (1) US20110046108A1 (fr)
EP (1) EP1981856A2 (fr)
JP (1) JP2009524632A (fr)
KR (1) KR20080089504A (fr)
CN (1) CN101374818A (fr)
AR (1) AR059218A1 (fr)
AU (1) AU2007209126B2 (fr)
BR (1) BRPI0707284A2 (fr)
CA (1) CA2640375A1 (fr)
IL (1) IL192610A0 (fr)
NO (1) NO20083059L (fr)
NZ (1) NZ569763A (fr)
TW (1) TW200736232A (fr)
UY (1) UY30107A1 (fr)
WO (1) WO2007085833A2 (fr)
ZA (1) ZA200806153B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
EP2161275A1 (fr) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Promédicaments de composés de 2,4-pyrimidinédiamine et leurs utilisations
KR101411695B1 (ko) 2006-02-17 2014-07-03 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
CA2673125C (fr) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
CA2687943A1 (fr) * 2007-04-27 2008-11-06 Astrazeneca Ab Nouveaux derives de n' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diaminepyrimidine en tant qu'inhibiteurs de ephb4 kinase pour le traitement d'etats proliferatifs
EA201000101A1 (ru) 2007-07-16 2010-08-30 Астразенека Аб Производные пиримидина 934
WO2009010794A1 (fr) * 2007-07-19 2009-01-22 Astrazeneca Ab Dérivés de 2,4-diamino-pyrimidine
US8436038B2 (en) * 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
KR101956261B1 (ko) 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
CN101659659B (zh) * 2008-08-29 2013-01-02 和记黄埔医药（上海）有限公司 嘧啶衍生物及其医药用途
WO2010072155A1 (fr) * 2008-12-26 2010-07-01 复旦大学 Dérivé de pyrimidine, sa méthode de synthèse et ses applications
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
CA2785738A1 (fr) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Modification covalente de proteine, dirigee sur un ligand
EP2536696A1 (fr) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Dérivés de la pyrimidine
WO2011120025A1 (fr) * 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines utilisés en tant qu'inhibiteurs de kinase
EP2395001A1 (fr) 2010-05-21 2011-12-14 Chemilia AB Nouveaux dérivés de pyrimidine
CA2798578C (fr) 2010-05-21 2015-12-29 Chemilia Ab Nouveaux derives de pyrimidine
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
EP2635284B1 (fr) 2010-11-01 2019-12-18 Celgene CAR LLC Composés hétérocycliques et leurs utilisations
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
EP2502924A1 (fr) 2011-03-24 2012-09-26 Chemilia AB Nouveaux dérivés de pyrimidine
RU2013147417A (ru) 2011-03-24 2015-04-27 Кемилиа Аб Новые производные пиримидина
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2013054351A1 (fr) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Composés hétérocycliques
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
CA2866857C (fr) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Sels d'inhibiteur de kinases du recepteur de facteur de croissance epidermique
WO2013169401A1 (fr) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Composés pour inhiber la prolifération cellulaire dans les cancers induits par l'egfr
EP2711364A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
EP2711365A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
CA2890006C (fr) * 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Inhibiteurs de kinase alk
EP2935226A4 (fr) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc Composés hétéroarylés et leurs utilisations
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formes et compositions d'un inhibiteur d'erk
WO2017181177A1 (fr) * 2016-04-15 2017-10-19 Epizyme, Inc. Composés aryle ou hétéroaryle à substitution amine utilisés comme inhibiteurs de ehmt1 et ehmt2
AU2018254577A1 (en) 2017-04-21 2019-12-05 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
IL271973B (en) 2017-07-28 2022-08-01 Yuhan Corp An improved process for the preparation of aminopyrimidine derivatives
CN111234067B (zh) * 2018-11-29 2021-08-03 中国石油化工股份有限公司 用于烯烃聚合的固体催化剂组分和催化剂及其应用
CN113801108B (zh) * 2020-06-16 2024-02-27 中国药科大学 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
US20230373960A1 (en) * 2020-09-22 2023-11-23 Beigene, Ltd. Indoline compounds and derivatives as egfr inhibitors
WO2022068849A1 (fr) * 2020-09-30 2022-04-07 Beigene, Ltd. Composés bifonctionnels pour la dégradation de l'egfr et procédés d'utilisation associés
WO2024071415A1 (fr) * 2022-09-30 2024-04-04 日本ポリケム株式会社 Composé, complexe métallique, composition de catalyseur pour la polymérisation d'oléfines, catalyseur pour la polymérisation d'oléfines et procédé de production de polymère d'oléfine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012485A1 (fr) * 1998-08-29 2000-03-09 Astrazeneca Ab Composes de pyrimidine
AU3704101A (en) * 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US7105530B2 (en) * 2000-12-21 2006-09-12 Smithkline Beecham Corporation Pyrimidineamines as angiogenesis modulators
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (fr) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
AU2003231231A1 (en) * 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
ES2325440T3 (es) * 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
CA2533320A1 (fr) * 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
WO2006129100A1 (fr) * 2005-06-03 2006-12-07 Glaxo Group Limited Nouveaux composes

Also Published As

Publication number Publication date
AR059218A1 (es) 2008-03-19
EP1981856A2 (fr) 2008-10-22
CN101374818A (zh) 2009-02-25
CA2640375A1 (fr) 2007-08-02
JP2009524632A (ja) 2009-07-02
ZA200806153B (en) 2009-07-29
UY30107A1 (es) 2007-08-31
WO2007085833A2 (fr) 2007-08-02
BRPI0707284A2 (pt) 2011-04-26
KR20080089504A (ko) 2008-10-06
WO2007085833A3 (fr) 2007-09-27
US20110046108A1 (en) 2011-02-24
TW200736232A (en) 2007-10-01
AU2007209126A1 (en) 2007-08-02
NZ569763A (en) 2012-06-29
IL192610A0 (en) 2009-08-03
AU2007209126B2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
NO20083059L (no) Pyrimidinderivater
SE0402735D0 (sv) Novel compounds
GB0612423D0 (en) Therapeutic agents
NO20081217L (no) Nye benzotiazolonderivater
NO20081582L (no) Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20090628L (no) Pyridizinon derivativater
SG170069A1 (en) Quinoline derivatives
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20071703L (no) Kinazolinderivater
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
TW200833675A (en) Nicotinamide derivatives
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
TW200639156A (en) New compounds
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application